DEXA Bone Density: Medication-Driven Changes, Normal Ranges, and Optimal Targets

What a DEXA scan actually measures

DEXA passes two low-dose X-ray beams through bone and calculates areal bone mineral density (BMD) in g/cm². The result is converted into two standard scores: the T-score, compared with peak bone mass in a young healthy adult of the same sex, and the Z-score, compared with people your own age and sex. Both the lumbar spine (L1-L4) and the proximal femur (total hip and femoral neck) are typically measured. DEXA is not the same test as a heel ultrasound or a quantitative CT bone density study; those use different reference ranges and are not interchangeable with DEXA T-scores for diagnostic classification.

The World Health Organization's 1994 diagnostic criteria define bone status by T-score alone in postmenopausal women and men aged 50 and older: normal at -1.0 or above, osteopenia from -1.0 to -2.5, and osteoporosis at -2.5 or below. This classification is widely adopted in clinical practice and remains the standard reference framework, though it was originally derived for epidemiologic screening rather than as an individual treatment trigger.

The Z-score matters more in premenopausal women, men under 50, and children, where comparing to a young-adult peak is not clinically meaningful. A Z-score meaningfully below average for age is generally treated by specialty societies as a signal to look for a secondary cause of bone loss rather than to diagnose primary osteoporosis.

A single T-score is not, by itself, a treatment threshold. Most current guidelines base the decision to start medication on an estimated 10-year fracture probability (commonly calculated with the FRAX tool), combined with the T-score, not the T-score in isolation. That distinction is the central practical point of this page: readers and clinicians who chase a specific number on a single scan, rather than tracking risk and change over time, are answering the wrong question.

Precision matters more than the second decimal point

DEXA scanners have measurement variability, commonly cited in the low single digits as a percentage at the lumbar spine, and the International Society for Clinical Densitometry (ISCD) defines a "least significant change" (LSC), the smallest change between two scans that can be called real rather than noise. Published LSC figures are typically in the range of roughly 3 to 4 percent at the spine, though the exact value depends on the machine and the technologist performing the scan and should be confirmed with the scanning center. This is the practical reason most guidelines recommend waiting one to two years between monitoring scans instead of repeating every six months: a change smaller than the LSC cannot be distinguished from scanner variability, and reacting to it as if it were a treatment failure or success is a common misinterpretation.

What counts as a normal range versus an optimal target

The WHO threshold defines a floor, not a goal. A T-score of -1.0 is classified as normal, but a T-score closer to 0.0, meaning bone density close to the average healthy 30-year-old, carries meaningfully lower fracture risk than a T-score sitting just inside the normal range. Landmark cohort studies of postmenopausal women and older men have shown that each standard deviation decline in femoral neck BMD is associated with a substantially higher relative risk of hip fracture, on the order of a two- to threefold increase per standard deviation in widely cited historical cohort data; the exact multiplier varies by study population and should be checked against the specific cohort before being quoted as a fixed number.

Decision framework: what should actually happen after a DEXA result

This framework is meant to organize a conversation with a clinician, not to replace one. It sequences the questions in the order they should be asked, because skipping ahead to "what drug" before answering the earlier questions is a common error.

Step 1: Is the T-score the right score for this person? If the patient is a postmenopausal woman or a man 50 or older, use the T-score. If the patient is premenopausal, a man under 50, or a child, use the Z-score instead and consider a secondary-cause workup if it is meaningfully below the age-expected range, rather than applying the WHO osteoporosis cut point.

Step 2: Does the score alone already meet a treatment threshold? A T-score of -2.5 or lower at the spine, total hip, or femoral neck is treated as an osteoporosis diagnosis by essentially every major guideline and is a near-universal trigger for a pharmacotherapy discussion, independent of other risk factors.

Step 3: If the score is in the osteopenia range, what does the fracture-risk calculation say? For a T-score between -1.0 and -2.5, run a validated 10-year fracture risk estimate (FRAX or an equivalent tool) incorporating age, prior fracture, parental hip fracture, glucocorticoid use, smoking, alcohol use, and rheumatoid arthritis. Some patients with osteopenia by T-score alone will still cross commonly used treatment thresholds because of these added risk factors; some patients with a T-score near -2.4 will not, if their overall risk profile is otherwise low. The number itself matters less than whether it crosses the threshold your clinician's guideline uses.

Step 4: Is this patient a candidate for anabolic-first therapy rather than a bisphosphonate? Very low T-scores (commonly cited around -3.0 or below), multiple prior fragility fractures, or a very high calculated fracture probability are the settings where guidelines discuss starting with an anabolic agent (teriparatide, abaloparatide, or romosozumab) before transitioning to an antiresorptive, rather than starting with a bisphosphonate. This sequencing decision belongs to a specialist managing osteoporosis, not to a self-directed reading of a DEXA report.

Step 5: When the repeat scan comes back, is the change real? Compare the change to the scanning center's stated least significant change. A change smaller than the LSC is noise, not a verdict on whether the medication is working. A change larger than the LSC in the wrong direction should prompt a search for secondary causes (see below) before assuming the drug has failed.

Step 6: If BMD looks stable or worse than expected, has a secondary cause been ruled out? Vitamin D deficiency, inadequate calcium intake, primary hyperparathyroidism, hyperthyroidism, celiac disease, and other malabsorptive or endocrine conditions can blunt or reverse the expected response to therapy. This step is frequently skipped and is a common reason patients are mislabeled as "treatment failures."

Who gets screened, and when earlier screening applies

Screening guidance from major preventive-medicine bodies generally recommends DEXA for women starting at age 65, or earlier for postmenopausal women whose overall fracture risk profile matches or exceeds that of an average 65-year-old. Evidence supporting a specific screening age for men has historically been considered less robust than for women, and screening decisions in men are usually driven by individual risk factors rather than age alone.

Situations that commonly prompt earlier screening, regardless of a fixed age cutoff, include a fragility fracture after age 40, sustained glucocorticoid use, premature menopause, malabsorptive conditions such as celiac disease or inflammatory bowel disease, prolonged amenorrhea, male hypogonadism, and androgen-deprivation therapy. These are widely cited risk factors across guideline documents rather than a single validated checklist, and the decision to scan earlier should be individualized.

How much medications change DEXA numbers

The figures below reflect the general magnitude and direction of effect reported for major osteoporosis drug classes in the endocrinology literature and in trials that are widely cited in clinical guidelines (including the trials commonly known as FIT, HORIZON-PFT, the pivotal teriparatide fracture trial, ACTIVE, ARCH, the WHI bone substudy, and the Testosterone Trials). The specific percentage figures inherited from earlier drafts of this material could not be verified against primary sources for this revision. They are presented here as approximate, directionally reliable ranges, and any precise number used for patient counseling or a clinical decision should be checked against the original trial publication before use.

Bisphosphonates (alendronate, risedronate, zoledronic acid) inhibit osteoclast-mediated bone resorption. Multi-year randomized trials in postmenopausal women have generally reported lumbar spine BMD gains in the mid-single-digit to high-single-digit percentage range over roughly three years, alongside reductions in vertebral fracture risk reported in the range of roughly 40 to 70 percent relative risk reduction depending on the specific trial and agent. Oral weekly dosing (alendronate, risedronate) and annual intravenous dosing (zoledronic acid) are both first-line options; the choice often comes down to gastrointestinal tolerability and adherence.

Parathyroid hormone analogues (teriparatide, abaloparatide) are anabolic, meaning they stimulate new bone formation rather than only suppressing resorption. Pivotal trials over roughly 18 to 24 months reported larger and faster lumbar spine BMD gains than bisphosphonates, generally in the high-single-digit to low-teens percentage range, with reported reductions in new vertebral fracture risk in a similar broad range to bisphosphonates or somewhat higher. Both agents carry a boxed warning related to osteosarcoma risk in patients with prior skeletal radiation or Paget's disease, and teriparatide use is capped at a defined lifetime duration; these details should come from the current FDA label, not from this page.

Romosozumab is a sclerostin inhibitor with a dual mechanism, stimulating formation while also suppressing resorption. The pivotal trial comparing romosozumab followed by alendronate against alendronate alone reported lumbar spine BMD gains in the low-to-mid teens percentage range at 12 months, larger than the alendronate-only comparator, with a lower rate of new vertebral fracture at 24 months in the romosozumab-first sequence. Romosozumab carries a boxed warning for cardiovascular events and is contraindicated within one year of a prior myocardial infarction or stroke; current labeling and contraindications should be confirmed directly with the FDA label rather than assumed from this summary.

Hormone replacement therapy (HRT) suppresses osteoclast activity through estrogen. The Women's Health Initiative bone substudy reported total hip and spine BMD gains in the low-to-mid single-digit percentage range over three years in the combined estrogen-progestogen arm, alongside reductions in hip and vertebral fracture risk in the roughly one-third relative risk reduction range in the full WHI trial. HRT is not FDA-approved as a first-line osteoporosis treatment for most postmenopausal women and its use for bone protection specifically should be weighed against its broader cardiovascular and cancer risk profile with a clinician, not decided from a DEXA report alone.

Testosterone replacement therapy in hypogonadal men raises BMD mainly through aromatization to estradiol; a placebo-controlled trial in older men with low testosterone reported meaningful lumbar spine and femoral neck BMD gains over one year of treatment, and co-administration of an aromatase inhibitor blunted the skeletal benefit, supporting an estrogen-mediated mechanism. Testosterone therapy is not FDA-approved specifically as an osteoporosis treatment; any bone benefit in a hypogonadal man is a secondary effect of treating documented hypogonadism, not an independent indication.

Monitoring on therapy and interpreting drug holidays

Guidance bodies including the ISCD generally support repeat scanning at one- to two-year intervals until BMD is stable (two consecutive scans within the LSC of each other), then extending the interval. Modest BMD gains on DEXA appear to underestimate the fracture-risk reduction seen in trials, particularly for bisphosphonates, which is thought to reflect improvements in bone microarchitecture that DEXA does not directly capture; this is a plausible explanation supported by the general shape of the trial data rather than a fully settled mechanistic fact.

Because bisphosphonates remain bound to bone mineral and continue exerting an antiresorptive effect after the drug is stopped, a planned pause ("drug holiday") after several years of oral or intravenous therapy is discussed in guidelines for lower-risk patients. Holiday duration is an individualized decision based on a repeat fracture-risk calculation and site-specific BMD at the time of discontinuation, not a fixed interval that applies to everyone, and it is not appropriate for patients with a T-score at or below -2.5 or a prior hip fracture.

Before concluding that a medication has "failed" because BMD did not rise as expected, guidelines call for ruling out secondary causes of bone loss: vitamin D deficiency, inadequate calcium intake, hyperparathyroidism, hyperthyroidism, celiac disease, renal osteodystrophy, and malabsorptive conditions. Endocrinology literature has described secondary causes as accounting for a substantial minority of apparent treatment failures in postmenopausal osteoporosis, though the exact proportion varies across sources and should not be quoted as a single fixed percentage without checking the source study.

Calcium, vitamin D, and exercise as the baseline, not an alternative

No pharmacotherapy is expected to work optimally on top of inadequate calcium or vitamin D. Commonly cited targets are roughly 1,000 mg/day of elemental calcium for younger adults and 1,200 mg/day for women over 50 and adults over 70, with vitamin D intake commonly targeted at 600 to 800 IU/day for most adults and a serum 25-OH vitamin D level above 30 ng/mL often used as a treatment target in patients being managed for osteoporosis; exact targets vary by guideline and by individual risk and should be set with a clinician.

Resistance and weight-bearing exercise produce a measurable, if modest, osteogenic stimulus, generally reported as a low single-digit percentage BMD gain at the spine over six to twelve months in trial data, smaller than pharmacotherapy but compounding over years and carrying independent benefits for muscle mass and fall prevention that DEXA does not capture. Smoking and heavy alcohol use are independent risk factors in most fracture-risk calculators and should be addressed regardless of medication status.

Evidence boundary: what is established, what is plausible, what is not

Established: DEXA T-score thresholds for diagnosing osteopenia and osteoporosis in postmenopausal women and men 50 and older; the general direction and rough magnitude of BMD change produced by bisphosphonates, PTH analogues, romosozumab, and estrogen therapy, each supported by randomized trial evidence; the principle that a BMD change smaller than the scanner's least significant change should not be treated as a real change; the recommendation to screen most women starting around age 65.

Plausible but not fully settled: The exact multiplier by which each standard deviation of BMD decline raises fracture risk in a given population; the precise proportion of "treatment failures" attributable to secondary causes; the degree to which DEXA-measured BMD gain versus actual fracture-risk reduction diverges by drug class, which appears real in trial data but is not fully mechanistically explained.

Not established from the material available here: Precise, current percentage effect sizes for each drug class down to a specific decimal, current FDA label language and boxed warnings (which change over time and must be checked against the live label), and individualized treatment thresholds for a specific reader's FRAX score, which requires an actual calculation with that person's inputs, not a generic number from an article.

When to seek care rather than rely on a DEXA report alone

A DEXA result showing a new fragility-range fracture on imaging, a very low T-score (commonly discussed as -3.0 or below), or a sharp unexpected drop between two scans warrants a prompt conversation with the ordering clinician rather than watchful waiting. Sudden new back pain with height loss can indicate a vertebral compression fracture and should be evaluated urgently, since it can occur without a clear traumatic event in someone with low bone density.

A note on sources for this revision: the original citation list attached to this article (PubMed identifiers and a WHO technical report link) could not be verified as accurately supporting each specific claim during this revision, and no reliable primary-source search results were available to replace them. Rather than carry forward unverified identifiers, this draft describes the underlying trials by name and general finding and flags precise percentages as approximate pending verification against the primary literature (including the FIT, HORIZON-PFT, teriparatide fracture prevention trial, ACTIVE, ARCH, WHI bone substudy, Testosterone Trials, and FLEX extension study). A qualified reviewer should confirm exact effect sizes, current FDA boxed warnings, and current screening-age guidance against primary sources and current drug labels before this page is published.